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Objective: To propose a standardized model for exercise-induced cartilage turnover and investigate residual levels
and dynamics of biomarker serum ARGS (sARGS) in primary osteoarthritis (OA) patients and a supportive group
of young healthy subjects.
Method: The trial is a randomized, cross-over, exploratory study with interventions of exercise and inactivity. 20
subjects with knee OA, as well as 20 young healthy subjects (mean age 25.7 years (range; 19–30), 50% male),
underwent cycling, running and resting interventions on separate days one week apart. Blood samples were taken
at baseline, immediately, 1, 2, 3 and 24 h after activity start. sARGS was measured by sandwich ELISA.
Results: Intraclass correlation between visits were 0.97 and 0.77 for the OA and healthy group, respectively. An
acute drop in sARGS in response to high-intensity exercise was observed in both groups. Minute acute sARGS
increase was observed in OA subjects in response to moderate intensity running and cycling, which normalized
within 24 h. In healthy subjects an acute drop in sARGS was seen immediately after running, but not cycling, and
no other changes were observed. A negative correlation between baseline Kellgren-Lawrence (KL) grade and
baseline sARGS (r ¼ 0.69, p ¼ 0.002) in OA was found. A negative correlation between age and sARGS was
found in healthy subjects (r ¼ 0.67, p ¼ <0.002).
Conclusion: sARGS sensitivity to physical activity is considered low and sARGS is a reproducible and stable
marker. Minute acute increases in sARGS were observed in the hours following moderate intensity exercise.1. Introduction
Change of life-style is known to be beneficial [1] and in general
physical activity is recommended to maintain mobility in Osteoarthritis
(OA) [2]. Optimal loading of cartilage may promote anti-catabolic and
anabolic effects in cartilage [3,4]. Yet, the acute impact of different ex-
ercise programs remains to be evaluated, although the joint load, and
thus the effect, of running vs. cycling is considered different, and mayal Sciences, University of Copenh
. Bjerre-Bastos), hbn@sanosclinic
rdicbio.com (A.-C. Bay-Jensen), m
International (OARSI). Publishedpresent different clinical utility.
Joint specific biochemical markers have become important tools in
OA research and development, where they are usually applied in the
investigation of disease modifying OA drug (DMOAD) candidates. Here
they may be used to optimize study populations [5], evaluate progression
[6] as well as treatment response [7]. Potential use also includes early
detection of OA [8], assessment of cartilage receptiveness to load [9],
determination of safe forms of exercise [10] and ability to adapt [11]. Itagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
.com (H.B. Nielsen), jra@nordicbio.com (J.R. Andersen), yhe@nordicbio.com
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establish their significance. Thus, biochemical markers must be charac-
terized and validated [12].
DMOAD trials are costly and time-consuming large studies [13]. A
low-cost model for rapid assessment would therefore be advantageous.
Such a model could evaluate potential chondroprotective properties of
DMOAD, based on changes in evoked cartilage turnover after joint-load.
To our knowledge, no standardized human model for assessment of
evoked cartilage turnover has previously been described.
Biochemical markers of cartilage turnover, such as cartilage oligo-
meric matrix protein (COMP), have been widely studied and are known
to increase following weight-bearing exercise in healthy individuals
[10]. A few studies, heterogeneous in design, investigated the
biochemical marker's response in OA subjects following exercise
[14–17], all of which acutely increased serum COMP. Furthermore,
studies found mechanically induced changes in biomarkers to be asso-
ciated with cartilage thinning after 5 years [14,18].
Aggrecan is a major component of articular cartilage extra cellular
matrix (ECM) [19], but may to a lesser extend be present in ECM of other
organs [20], such as veins [21]. Increased turnover is expected in
response to load stress, and subsequent changes in serum concentrations
of aggrecan fragments may therefore reflect the degree of induced
cartilage turnover. A fragment of aggrecan, the ARGS neoepitope, has
previously been proposed as a promising prognostic and pharmacody-
namic marker in OA drug development [22].
The ARGS neoepitope is generated enzymatically by A disintegrin and
metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) [23] and
is thought to reflect cartilage turnover [24]. ARGS has primarily been
investigated in synovial fluid (SF) of knee trauma subjects, where it has
been observed to increase after injury [25–27]. Levels of ARGS in SF are
also increased in knees affected by OA [26] as compared to healthy in-
dividuals. However, concentrations in SF can [25], but may not always
reflected in serum [22,28]. Serum ARGS (sARGS) has been investigated
in a single cross-sectional study including OA subjects [22] and was
found to be associated with OA disease severity and age, while the dy-
namics of sARGS in OA still represents a gap in the literature.
The objectives of this exploratory pilot study were to propose a
standardized model for exercise-evoked cartilage turnover and investi-
gate sARGS dynamics, residual levels and changes in response to exercise
of various mechanical loading in human knee OA subjects and a sup-
portive group of young healthy individuals. We aimed to evaluate the
feasibility of the model and, further characterize sARGS as a biomarker of
cartilage turnover in OA.
2. Methods
2.1. Study design
This pilot study was an exploratory, randomized, cross-over trial with
exercise intervention of OA subjects and a supportive group of young
healthy individuals. Participants from both groups underwent two active
interventions in a randomized order followed by a third “resting” inter-
vention. Study visits were scheduled with a one week interval to facilitate
“wash-out” of circulating biomarkers and participants were instructed beFig. 1. Overview of the m
2minimally active (e.g. no biking to the site) and to fast 6 h prior to visits.
For the purpose of conducting exercise-interventions at a comparable
intensity for all subjects, the maximal heart rate (HRmax) was determined
by HRmax-test performed prior to the first intervention. The outline of
study interventions is shown in Fig. 1.
2.2. Subjects
Twenty OA subjects and twenty healthy subjects were planned to be
enrolled. Subjects were recruited through advertisements on social
media and in the local paper. Inclusion criteria for the OA group were x-
ray verified Kellgren-Lawrence grade 1–3 in a least one tibio-femoral
joint, age 35–75 years and body mass index (BMI) between 18.5 and
35 kg/m2. Exclusion criteria were previous knee or hip arthroplasty,
arthroscopy or intra-articular injections of therapeutic agents within the
last 6 months, presence of autoimmune disease or secondary OA, treat-
ment with beta-blockers, corticosteroids or anticoagulants, active sys-
temic disease and history of cardiovascular disease, alcoholism/drug
abuse.
Inclusion criteria for healthy subjects were age 18–75 years, KL 0 and
BMI between 18.5 and 35 kg/m2. Exclusion criteria were osteoarthritis,
suspicion of osteoarthritis, previous knee or hip arthroplasty, arthroscopy
or intra-articular injections within 6 months, treatment with beta-
blockers, corticosteroids or anticoagulants, active systemic disease and
history of cardiovascular disease, alcoholism/drug abuse.
2.3. Procedures
At the screening visit demographics data, standard medical history
and physical activity history was obtained. Physical exam including vital
signs, ECG and bilateral knee x-ray was performed and subjects filled in
the KOOS Pain subscale (P1–P9).
A supervised HRmax-test was carried out on a spinning bike at visit
two during the screening period to experimentally establish the accurate
HRmax. The heartrate (HR) was monitored using a pulse belt and during
the entire test the investigator encouraged and motivated the subject in
order to reach the highest possible HR. Upon establishment of HRmax,
meeting all inclusion criteria and no exclusion criteria, the subjects were
randomized to a sequence of interventions as illustrated in Fig. 1. We
aimed to assess the difference between the experimental and calculated
(theoretical) HRmax for future reference.
Instructions were given to be minimally physically active on the day
before and the day of intervention, both active and resting. On days of
active intervention, subjects were instructed to meet after fasting for 6 h
and maintain fasting until all samples were taken. Only intake of water
was allowed during fasting. Subjects were equipped with a heart rate
monitor and a blood sample was taken a baseline (approximately 5 min
before initiation of activity). Running was carried out on a treadmill and
cycling was carried out on a spinning bike. Activity was initiated with a
10 min warm-up walk at a HR below 75% of HRmax before running.
Cycling was initiated with a 10 min cycling warm-up at a HR below 75%
of HRmax. After the warm-up the intensity running speed and tread load,
respectively, was regulated in order to quickly reach and maintain a HR
of 75% of HRmax for 15 min. A cool-down of 5 min of walking andain study procedures.
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sample was taken immediately after activity and 1, 2, 3 and 24 h after
intervention start. If participants were not able to complete the running
intervention, a rescue intervention of up-tempo walking with a similar
protocol was applied. The subjects were seated in the clinic lounge area
during the entire resting intervention and during the 2.5 h sampling
period after exercise. Blood samples were taken 5 times with the same
interval as during active intervention.
2.4. Recent physical activity history
Recent physical activity data was collected using a custommade semi-
qualitative instrument. Significant cardio work-out was defined as an
average of more than two weekly hours of self-reported significant cardio
work-out during the previous two months from screening. Self-reported
weekly hours and the type of significant work-out was recorded.
2.5. X-ray
X-ray images of both knees including femoral and tibial metaphyses
and proximal fibula were obtained to assess the KL grading and to rule
out significant knee pathology. A Syna-Flex™ device was used for
consistent positioning. Subjects were positioned with even weight-
distribution on both legs, flexing the knees until having the thighs in
touch with Syna-Flex™.
Images were analyzed by an experienced radiologist.
2.6. KOOS pain
KOOS is a self-explanatory questionnaire for assessment of the
patient's opinion about their knee problems considering the previous
week as the time period [29]. KOOS is also commonly used to assess
groups in knee OA research [29]. For each question, the subject responds
on a 5-point likert scale and assigned a score from 0 to 4. For data
analysis, the score is normalized using the formula: KOOS Pain ¼ 100 -
(Mean score x 100/4), Thus, a score of 100 indicates no symptoms and
0 indicates extreme symptoms.
2.7. ARGS neoepitope biomarker assay
The ARGS marker was measured using a chemiluminescence sand-
wich assay (huARGS), applying the monoclonal antibodies F78 against
the G2 domain and OA-1 targeting ARGS neoepitope was used as a
detection antibody [22]. In brief, a 96-well streptavidin pre-coated
microplate was coated with biotinylated F78 for 30 min at 20 C on a
shaker. Following five washes with wash buffer (20 mM Tris, 50 mM
NaCl, pH 7.2), 20 μL standards, controls or samples were added to
appropriate wells, followed by 100 μL of peroxidase labelled-OA-1 and
the plate was incubated overnight (20  1 h) at 4 C. After washing,
100 μL of chemiluminescence subtract was added and the plate was read
at a standard chemiluminescence reader. The detection range of the assay
was 41–2523 pmol/mL. Two kit controls and one in-house controls were
included where inter-assay CVs were <12%. Samples were run in du-
plicates and the median (range) intra-assay CV was 2.3 (0.1–17.6).
Samples with duplicate CVs above 15% were rerun.
2.8. Statistical analysis
No formal power calculations were performed to assess the sample
size in this exploratory study. The proposed sample size of 20 subjects in
each group was deemed sufficient for exploratory analysis of biomarker
changes. The two groups were investigated using the same method, but
not intended for comparison, and thus analyzed separately.
Missing values (i. e. due to lost samples) were registered and reported,
but were left out of analyses.
Baseline ARGS from samples, defined as the first set of samples taken,3from each intervention visit (running, cycling and resting) were used to
assess the inter-day variability of OA subjects and healthy volunteers
under standardized conditions (minimal physical activity and fasting).
Interday variability was calculated and assessed by repeated single
measures intra-class correlation coefficient (ICC). For correlation ana-
lyses “baseline ARGS” was defined as the sARGS concentration from the
first sample taken during rest and fasting.
Statistical significance of sARGS changes following HRmax-test was
assessed by paired T-test.
Mean proportional changes in sARGS from baseline and standardized
to resting values, respectively, were calculated and plotted with 95%
confidence intervals (CI).
The area under the curve (AUC) for time interval 0–3 h for each
intervention was calculated and evaluated by their 95% CI.
Multiple regression was used to examine factors influencing sARGS.
We adjusted for age, sex, BMI, KL grade (both highest and cumulated)
where applicable.
Statistical analyses were performed using MedCalc version 18.11.6.
GraphPad Prism 8 was used for graphs and associated calculations, such
as AUC and Spearman correlation.2.9. Permissions
Informed consent was obtained from all participants prior to enroll-
ment and data collection.
The procedures followed were in accordance with the ethical stan-
dards of the responsible committee on human experimentation (institu-
tional and national) and with the Helsinki Declaration of 1975, as revised
in 2000. The study was approved by National Ethical Committee
(approval number: H-18038807). The study was funded by Nordic
Bioscience and the Danish Research Foundation.
3. Results
3.1. Study overview
48 subjects were screened and 40 were randomized, resulting in 20
subjects in each group as planned. All enrolled subjects completed the
study. One subject was excluded from analysis as sARGS in this subject
was below the lower limit of the quantifiable range in all samples. A total
of four single samples were lost, one in the OA group and three in the
healthy group. The one lost sample from the OA group was a 3 h sample
after cycling. The three lost samples in the healthy group were all 24 h
follow-up samples – one after cycling and two after running. The over-
view of study populations is displayed in Fig. 2 and baseline character-
istics are displayed in Table 1.
The experimentally measured HRmax and the theoretical HRmax
differed 0.2% (SD: 5.9) in average, with the theoretical HRmax calculated
by the formula: HRmax ¼ 206.3*(0.711*age) [30]. As shown in Fig. 3, a
statistically significant decrease in the level of sARGS was found imme-
diately after the HRmax-test in both the OA (p < 0.05) and the healthy
group (p < 0.001).
The mean sARGS changes from baseline were calculated for each
intervention in both groups and listed in Table 2.3.2. Technical performance of the ARGS assay
Technical performance of ARGS assay: Intra- and inter-assay varia-
tions were 1.7–2.1% and 4.8–9.6%, respectively. The lower limit of
detection was 25.7 pM and the quantifiable range was between 83.1 and
1329 pM.
The interday-variability was relatively low, particularly in the OA
group, as displayed in Fig. 4a–b, and the ICC, which is ideally 1.0, was
calculated as 0.97 (95% CI: 0.94–0.99) for OA subjects and 0.77 (95% CI:
0.57–0.89) for healthy subjects.
Fig. 2. CONSORT chart of the study populations and enrollment. Two OA
subjects were screen-failed due to post-traumatic OA and five were screen-failed
due to x-ray verified KL grade 4. One healthy subject was screen-failed due to x-
ray verified OA. One OA subject was excluded from analysis, as sARGS was
below the lower limit of the quantifiable range in all samples.
Table 1
Baseline characteristics for study subjects included for analysis.
OA subjects
(N ¼ 19)
Healthy subjects
(N ¼ 20)
Mean age, years (R) 61.9 (9.1) 25.7 (3.82)
Male sex, n (%) 5 (26.3) 10 (50)
Mean BMI (kg/m2) (SD) 26.3 (3.4) 22.5 (1.6)
Highest KL-grade at baseline, n
(%)
1: 3 (15.8) 0
2: 7 (36.8)
3: 9 (47.4)
Mean ARGS (pmol/L) (SD) 348 (209) 428 (93.6)
Mean KOOS Pain (SD) 74.4 (11.4) 95.1 (8.1)
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Twenty subjects completed the cycling and resting interventions and
provided measurable levels of sARGS, 15 subjects completed running,
while 5 subjects completed the rescue intervention instead of the running
intervention.
As shown in Fig. 5aþb, mean sARGS trended to decrease from base-
line shortly after exercise and subsequently increased one, two and 3 h
after initiation of exercise. sARGS levels returned completely to baseline
levels the day after cycling, but appeared slightly elevated the day after
running. sARGS initially decreased and returned to baseline levels during
3 h of rest. The magnitude of the observed changes was generally small,
and did not exceed 6.7% at any time point. Standardizing sARGS to
resting levels appeared to accentuate the trend of increase, as seen on
Fig. 5b. The area under the curve for the time interval 0–3 h was calcu-
lated for each graph in Fig. 5aþ b, but none of the AUCs were statistically4significant from baseline or from the other interventions.
A negative correlation between cumulated KL grade and baseline
sARGS (rpartial ¼ 0.69, p ¼ 0.002) (without the single outlier,
rpartial ¼ 0.62, p ¼ 0.01), and a positive correlation with age and
baseline sARGS (rpartial ¼ 0.67, p ¼ 0.003) (without the single outlier,
rpartial ¼ 0.27, p ¼ 0.33) was found.
No statistically significant correlations were found between sex,
physical activity history or pain and sARGS.
3.4. Healthy subjects
20 healthy participants completed the interventions.
As shown in Fig. 5c and d, sARGS decrease significantly shortly after
running, but not after cycling. Subsequently sARGS trended to rise above
baseline levels after two and 3 h, respectively. sARGS returned to base-
line levels the day after running, but was still elevated the day after
cycling. sARGS trended to increase during 3 h of rest.
AUCs for Fig. 5c and d were calculated and compared by their 95%
CIs. None of the AUCs were significantly different from 0 or from the
other AUC of the other interventions.
A negative correlation was found between age and baseline ARGS,
adjusted for covariates (rpartial ¼ 0.67, p ¼ 0.002). The univariate
correlation is plotted in Fig. 6.
No statistically significant correlations were found between sex,
physical activity history or pain and sARGS.
4. Discussion
The existing literature on the impact of exercise on OA biomarkers is
sparse, while healthy subjects have been widely studied [10]. This study
applied a proposed model for evaluation of acute cartilage turnover after
exercise and we report novel data on sARGS acute dynamics in human
subjects.
4.1. Osteoarthritis
The overall results of this pilot study indicate that 1) the model is
feasible for knee OA subjects, 2) sARGS sensitivity to physical activity is
low, 3) sARGS is a valid reproducible marker as judged by the ICC of 0.97
reflecting minimal interday variability comparable to previous research
on like biomarkers [31]. 4) A relatively large difference in the variation
of baseline aggrecan turnover between subjects was observed, and the
turnover rate remained stable for each subject throughout the study 5) a
transient drop in sARGS is seen immediately after exercise which may be
inversely proportional to exercise intensity 6) the results suggest a cor-
relation between mechanical load and sARGS elevation, although the
proportions of increase was low considering the load intensity. sARGS
may continue to rise after the last sampling point 3 h after initiation of
the exercise intervention, but was not sampled in the period between 3 h
and approximately 24 h after initiation of exercise.
A higher cumulated KL grade correlated with a lower sARGS level. A
possible explanation may be that a lower volume of cartilage results in
lower ARGS release. Previously, sARGS has been observed to positively
correlate with KL grade, which is contradictory [22]. However, the
methodological differences, including structural severity, assessment of
function and pain and OA subtype (only primary OA in this study) of the
present and referred study limits the possibilities for direct comparison,
and the reason for this discrepancy is unknown. The positive correlation
between sARGS and age, and the absence of gender-based differences
observed are in line with results from the other existing study on sARGS
in human OA [22].
ADAMTS-5 is increased in human OA cartilage [32] and fragments of
aggrecan including ARGS have previously been proposed as an early
marker of OA progression [22,33]. Our results support that sARGS reflect
aggrecan-, and thus presumably, cartilage turnover [33], although the
potential contribution from cardio-vascular system is unknown. In
Fig. 3. Acute changes were seen in sARGS following short high intensity exercise. Absolute sARGS concentrations before and after HRmax-test in OA (a) and healthy
subjects (b) are plotted. Paired t-test was applied on 20 pairs in both groups.
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suggest that sARGS is further evaluated as a biomarker in OA e.g. as a
predictor of structural progression during a longer period of time (years).
If found to be associated with risk of progression, sARGS used in a
standardized exercise model could be valuable in early evaluation of
DMOADs e.g. for evaluation of ADAMTS-5 monoclonal antibodies [34].
However, this needs further investigation.4.2. Healthy subjects
sARGS decreased after the HRmax-test and after the running inter-
vention in healthy subjects. This is in line with the weaker trends of
initial decrease in the OA group and the significant decrease following
the HRmax-test in the OA group. The reason for this transient drop is
unknown, but it may be due to redistribution, metabolism, capillary
leakage or a combination as a consequence of the cardiovascular stress.
Another speculative explanation may be that acute intra-articular anti-
inflammatory effects, which are known to be associated with exercise
[17], temporarily reduce the activity of inflammation-sensitive pro-
teases, such as MMPs and ADAMTS [35]. sARGS increased from baseline
during rest and no considerable increase was observed following either
exercise intervention. The findings were surprising in the context of a
previous studies where dose-response relationship was observed between
COMP and joint load [9], and proteoglycan fragment levels increase [36,
37].
The ICC of 0.77 in healthy subjects indicated a slight interday vari-
ability in sARGS in young healthy subjects. This interday variation,
however, may have been negatively affected by only a few specific
subjects, as most ARGS results were similar between the measured
baseline visits. This could be a result of physical activity performedTable 2
Mean absolute change (pmol/L (SD)) Mean proportio
Group (n) 30 min 60 min. 120 min. 180 min. 24 h 30 min 60 m
Cycling
(OA) (19)
- 3.9
(23.3)
1.36
(21.0)
3.2
(25.0)
8.6
(27.9)
5.9
(47.1)
1.6
(5.7)
1.9
(6.5)
Running
(OA) (14)
7.1
(27.9)
2.9
(17.0)
2.9
(14.2)
8.5
(19.8)
2.5
(20.9)
2.3
(7.0)
1.5
(5.5)
Walking
(OA) (5)
19.4
(42.1)
21.2
(43.3)
17.0
(55.9)
23.0
(53.1)
19.4
(17.2)
1.7
(3.9)
1.2
(5.3)
Resting (OA)
(19)
2.2
(28.1)
0.1
(29.4)
1.6
(37.2)
6.7
(56.3)
N. a. 0.6
(8.3)
2.8
(8.0)
Cycling
(Healthy)
(20)
3.6
(31.1)
1.8
(29.9)
7.7
(29.7)
7.0
(31.9)
8.5
(42.8)
- 0.7
(7.2)
- 0.6
(6.9)
Running
(Healthy)
(20)
16.8
(23.7)
5.8
(20.3)
0.8
(25.2)
4.5
(26.4)
0.7
(34.8)
3.6
(5.5)
1.0
(4.2)
Resting
(Healthy)
(20)
5.0
(32.0)
10.4
(29.8)
7.1
(27.9)
15.0
(41.0)
N. a. 0.6
(7.8)
2.5
(7.2)
5between visits, but as no measure of background physical activity was
collected, the exact reason for this phenomenon is unknown.
The negative correlation between age and baseline sARGSmay reflect
changes in synthesis rates of aggrecan, which have previously been found
to decline with age [38]. A component here may likely be the closing of
the chondral epiphyseal growth plates, which occurs in early adulthood
[39]. This correlation is opposite of that seen in OA, which supports a
fundamental difference in the significance of sARGS as a biomarker in
subjects with and without OA, or a bi-phasic association as a function of
age. However, it is important to highlight that the age-ranges in the two
groups did not overlap, and thus direct comparison cannot be made.4.3. The model
Prior to the current study no standardized model to investigate the
acute impact of exercise on cartilage has been described. In a single study
on OA patients, the chondroprotective effect of glucosaminewas tested in
an exercise model. Serum COMP decreased significantly compared to
ibuprofen and placebo over 12-weeks of lower limb strength training
[40]. The study indicate that a model combining cartilage load and
biomarkers may be useful in assessing potential chondroprotective drugs.
Our proposed model is intended to induce standardized loading to major
joints at comparable cardiovascular stress, in order to measure the impact
on cartilage using biochemical markers.
In studies investigating acute biomarker changes, it is standard pro-
cedure to have the subjects rest in the follow-up sample period, in order
to detect the isolated effect of the exercise-intervention, but since com-
plete rest itself is an intervention, which affects the biomarkers, most
often in the opposite direction, complete rest may act as a partial counter-
interaction dampening the exercise-induced response, potentiallynal change (%) (SD) Change from corresponding resting sample
(%) (SD)
in. 120 min. 180 min. 24 h 30 min 60 min 120 min 180 min.
1.0 (7.4) 2.7 (8.5) 0.1
(10)
0.8
(15)
5.4
(15)
5.5 (20) 5.6 (18)
1.7 (5.4) 4.8 (9.1) 1.5
(7.8)
0.3
(12)
5.2
(13)
5.2
(9.7)
6.7 (12)
0.4 (6.6) 2.0
(5.5)
4.6
(4.5)
0.9
(9.4)
1.6
(12)
1.4 (10) 2.8
(12)
2.1
(7.5)
0.2
(10)
N. a. N. a. N. a. N. a. N. a.
1.9 (6.9) 1.5 (7.4) 2.9
(7.4)
1.5
(15)
2.9
(19)
- 0.2
(15)
3.8 (17)
0.5 (6.0) 2.0 (7.0) 0.1
(8.8)
0.5
(14)
0.3
(15)
2.8 (15) 2.1 (12)
1.4 (7.2) 3.5 (10) N. a. N. a. N. a. N. a. N. a.
Fig. 4. a) sARGS interday variation in OA patients. b) sARGS interday variation in healthy subjects.
Fig. 5. Mean proportional change in sARGS from baseline, T0 (immediately before exercise), in OA subjects (n ¼ 19) (a–b) and in healthy subjects (c–d).
Fig. 6. a) Correlation between KL-grade and sARGS. Spearman's r reported. b)
J.J. Bjerre-Bastos et al. Osteoarthritis and Cartilage Open 2 (2020) 100060resulting in a reduction of the magnitude of the measured biomarker
changes. A reason for this may be that the use of joints contributes to the
movement of biomarker from its tissue of origin, e.g. the knee joint, to the
bloodstream.
If refined, our method may facilitate identification of structural pro-
gressors [14] or ultimately assess response to structurally modifying
treatment substantially quicker than in settings without evoked tissue
turnover. However, the magnitude of sARGS response was relatively low,
with an average change from baseline of approximately 5%. Develop-
ment of the model might therefore include a combination of sARGS and
other biomarkers of cartilage turnover to include not only ADAMTS-5
derived aggrecan turnover, but also other important joint tissue pro-
cesses. As a minor finding, it was found that the HRmax-test may also be
replaced with a simple HRmax-calculation, as we found very high
concordance between the experimental and theoretical values in this
study population.Correlation between age and baseline ARGS in OA subjects. Spearman's
r reported.
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In the OA group age and male/female distribution was similar to that
of typical clinical trial OA cohort, however BMI was lower, compared to
the commonly described OA populations in clinical research. The char-
acteristics of the healthy group are considered typical for the age group.
The substantial differences in the age of the healthy and OA populations
prohibits direct comparisons between the groups, but as the study was
designed to compare within each of the two groups, and not across
groups, it does not influence the main study results.
We only included subjects with primary OA. Thus, the results of this
study does not necessarily reflect the pathological picture in secondary
OA, such as post-traumatic OA.
As matched series of blood samples were taken during rest and ex-
ercise intervention was crossed over, subjects act as self-controls. The
order of the exercise modalities was randomized. Prior to exercise in-
terventions all subjects had completed HRmax-test in order to 1) enable
standardization of the cardiovascular stress and 2) to neutralize the in-
fluence of potential plasma volume expansion after [41] the first
exercise.
The feasibility of weight-bearing exercise in OA patients such as
moderate intensity running, is not well described in the existing litera-
ture. Despite the presence of varying degree of joint damage and pain, the
type, intensity, and duration of the proposed exercise modalities were
considered feasible for the majority of the enrolled OA population,
which, regardless of the results of the study, is interesting as it suggests
good tolerability to moderately intense physical activity despite struc-
tural changes in the knee(s).
The most important limitation is the small sample size. The magni-
tude of the observed changes was relatively small, <10%, and it appears
that a larger sample size could have contributed beneficially to the sta-
tistical rigor.
Aggrecan, and thus ARGS, is considered to be widely present in
cartilage, but low amounts are present in veins. This may potentially
contribute to sARGS levels, but as the current study design does not
permit evaluation of tissue origin of aggrecan turnover, this is a limita-
tion. Further studies may seek to establish the potential cardio-vascular
contribution to sARGS levels.
The nature of this exercise-based model may have biased the study
population towards subjects with generally better fitness. Thus the re-
sults may not apply alike to OA patients with different characteristics, but
as all enrolled subjects met the radiographic criteria, the structural ele-
ments of the disease in the study are considered representative of other
OA patients regardless of their physical fitness.
5. Conclusion
Minute acute increases in sARGS were observed in the hours
following moderate exercise, possibly reflecting changes in cartilage
turnover. sARGS sensitivity to physical activity is considered low and
sARGS is considered a reproducible marker with stable individual levels
from visit to visit.
The findings support the use of sARGS in clinical OA research,
without a need to control for normal physical activity.
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